Search Patents
  • ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEIN
    Publication number: 20210388065
    Abstract: The present invention provides recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 16, 2021
    Applicants: ACTIVE MOTIF SHANGHAI LIMITED, SHANGHAI PUBLIC HEALTH CLINICAL CENTER, FUDAN UNIVERSITY, SHANGHAI PUBLIC HEALTH CLINICAL CENTER
    Inventors: Yanan LU, Fei LAN, Jianqing XU, Xi ZHAO, Longfei DING, Yongheng WANG, Jinkai WAN, Shenghui XING, Joseph FERNANDEZ
  • MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES
    Publication number: 20240100152
    Abstract: Recombinant polynucleotides including a nucleic acid sequence encoding an engineered SARS-CoV-2 spike protein (S12) or an immunogenic fragment thereof, in which the engineered spike protein or immunogenic fragment includes one or more mutations in the S2 segment of the S12 ectodomain. Vaccines, pharmaceutical compositions, and methods of use of the polynucleotides, vaccines, and pharmaceutical compositions in treating, alleviating, or managing SARS-CoV-2 infection and/or one or more symptoms thereof.
    Type: Application
    Filed: September 6, 2023
    Publication date: March 28, 2024
    Inventors: Pei Tang, Tommy Stevens Tillman, Yan Xu
  • HAPTENIZED CORONAVIRUS SPIKE PROTEINS
    Publication number: 20230149534
    Abstract: The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: David Berd, James Passin
  • HUMANIZED ANTIBODY FOR SARS-CoV-2 SPIKE PROTEIN INFUSION
    Publication number: 20220323345
    Abstract: An embodiment provides a method for treatment of the COVID-19 virus, including: preparing an intravenous infusion, wherein the intravenous infusion comprises at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; introducing the intravenous infusion to a patient; forming a virion antibody complex, wherein the virion antibody comprises the at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; and monitoring the virion antibody complex from a sample of a body fluid. Other aspects are described and claimed.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 13, 2022
    Inventors: Qiang Chen, Mitchell Steven Felder
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20210283245
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: May 26, 2020
    Publication date: September 16, 2021
    Inventors: Kayvan Niazi, Thomas King
  • EXPRESSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE PROTEIN SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME
    Publication number: 20230002780
    Abstract: A plant produced vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is provided where the Spike protein of the virus is expressed in a plant by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleic acid encoding the Spike protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. The plant expresses the 51 polypeptide at levels of at least 10 mg/kg of seed of said plant. When orally administered to an animal, a protective response is observed including a serum antibody response.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 5, 2023
    Inventors: John Howard, Erin Egelkrout
  • ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS
    Publication number: 20220023415
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 27, 2022
    Inventor: Thomas H. King
  • SARS-2 SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE
    Publication number: 20230310582
    Abstract: The invention provides SARS-2 spike protein designs and uses thereof.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 5, 2023
    Inventors: Rory Henderson, Kevin Saunders, Barton F. Haynes, Priyamvada Acharya
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20230302121
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 28, 2023
    Applicant: NantCell, Inc.
    Inventors: Kayvan Niazi, Thomas H. King
  • ADENOVIRUS PARTICLES HAVING A CHIMERIC ADENOVIRUS SPIKE PROTEIN, USE THEREOF AND METHODS FOR PRODUCING SUCH PARTICLES
    Publication number: 20110189234
    Abstract: The present invention is concerned with means and methods for producing adenovirus particles comprising a chimeric adenovirus spike protein that essentially lacks a functional knob domain. One aspect of the invention is concerned with a method for producing adenovirus particles comprising providing cells that are permissive for adenovirus replication with an adenovirus vector, with nucleic acid encoding said chimeric adenovirus spike protein and with nucleic acid encoding at least one adenovirus E3 region protein or a functional part, derivative and/or analogue thereof, said method further comprising culturing said permissive cells to allow for at least one replication cycle of said adenovirus virus and harvesting said adenovirus particle.
    Type: Application
    Filed: February 13, 2007
    Publication date: August 4, 2011
    Inventors: Victor Willem Van Beusechem, Frederik Hubertus Emanuel Schagen
  • 4/91 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
    Publication number: 20200129613
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Annika KRAEMER-KUEHL, Hans-Christian PHILIPP
  • Methods and compositions for chimeric coronavirus spike proteins
    Patent number: 9884895
    Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 6, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
  • METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS
    Publication number: 20170096455
    Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
    Type: Application
    Filed: March 20, 2015
    Publication date: April 6, 2017
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
  • H52 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
    Publication number: 20200129614
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Annika KRAEMER-KUEHL, Egbert Siegfried MUNDT, Hans-Christian PHILIPP
  • METHOD AND PLATFORM FOR ENHANCING DETECTION ACTIVITY OF INTERACTION BETWEEN SPIKE PROTEIN RECEPTOR BINDING DOMAIN OF CORONAVIRUS FROM SPECIMEN AND HUMAN ANGIOTENSIN-CONVERTING ENZYME II
    Publication number: 20220412959
    Abstract: The present disclosure provides a method and a platform for enhancing detection activity of an interaction between a spike protein receptor binding domain of coronavirus from a specimen and a human angiotensin-converting enzyme II. The method and the platform of the present disclosure use a cleavable luciferase as a report test for the combination of the spike protein receptor binding domain of coronavirus (such as novel coronavirus) and angiotensin-converting enzyme II. Screening is carried out at the cellular level. The strength of the drug's influence on the interaction between the two molecules can be judged by the strength of the luminescence signal. The detection time can be completed within 20 minutes.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 29, 2022
    Inventors: Hui-Ching Wang, Tian-Neng Li
  • Producing recombinant SARS-CoV-2 spike protein in a pre-fusion state
    Patent number: 11020474
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells). The pre-fusion state SARS-CoV-2 spike protein can be used as an antigen to generate antibodies/binding molecules for use in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; as a therapeutic to interfere with SARS-CoV-2 cellular binding; to generate antibodies/binding molecules to SARS-CoV-2 for use in therapy; or, as a vaccine for generating immunity to SARS-CoV-2; or for prophylactic or therapeutic use against related coronaviruses.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 1, 2021
    Inventors: Yang Xiang, Jun Li
  • H52 IBV vaccine with heterologous spike protein
    Patent number: 11696947
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: July 11, 2023
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Egbert Siegfried Mundt, Hans-Christian Philipp
  • 4/91 IBV vaccine with heterologous spike protein
    Patent number: 11224649
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: January 18, 2022
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
  • Method of Treating or Preventing Clinical Signs Caused by Infectious Bronchitis Virus with 4/91 IBV Vaccine having Heterologous Spike Protein
    Publication number: 20220265815
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: December 8, 2021
    Publication date: August 25, 2022
    Inventors: Annika KRAEMER-KUEHL, Hans-Christian PHILIPP
  • METHODS RELATED TO AN ALTERNATIVE CONFORMATION OF THE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20240274239
    Abstract: Described are methods related to a newly discovered alternative conformation of the SARS COV 2 Spike protein.
    Type: Application
    Filed: July 8, 2022
    Publication date: August 15, 2024
    Applicants: CZ Biohub SF, LLC, The Regents of the University of California
    Inventors: Susan Marqusee, Shawn M. Costello, Sophie R. Shoemaker
Narrow Results

Filter by US Classification